PhaseBio Pharmaceuticals, Inc.

77 articles with PhaseBio Pharmaceuticals, Inc.

• PhaseBio Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2021 on July 15

  6/30/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the upcoming William Blair Biotech Focus Conference 2021 taking place virtually on Thursday, July 15, 2021 at 1:00 pm – 1:45 pm EDT.

• PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab

  6/17/2021

  PhaseBio to host conference call today at 5:30 am PST / 8:30 am EST that it has entered into an exclusive licensing agreement with Alfasigma S.p.A.

• PhaseBio Highlights Real-World Healthcare Cost and Bleeding Cost Data Featured at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference

  5/20/2021

  Study leveraging the IBM® MarketScan® claims database examined healthcare resource utilization including total healthcare costs and bleeding costs in patients initiating P2Y 12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients receiving P2Y 12 inhibitors incurred total costs and bleeding-related costs similar to or greater than patients prescribed FXa inhibitors or dabigatran

• PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session

  5/17/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today highlighted real-world evidence presented over the weekend at The American College of Cardiology's 70th Annual Scientific Session.

• PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights

  5/13/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported first-quarter 2021 financial results.

• 

  Abingworth's $582 Million Co-Development Fund Will Propel Late-Stage Trials

  5/10/2021

  London-based venture capital fund Abingworth closed on a new Clinical Co-Development Fund now at $582 million. The fund's original target was just at $350 million.

• PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

  4/7/2021

  PhaseBio Pharmaceuticals to Present at 20 th Annual Needham Virtual Healthcare Conference

• PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  3/22/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the closing of an underwritten public offering of 18,400,000 shares of its common stock at a public offering price of $3.50 per share, including the full exercise of the underwriters’ option to purchase an additional 2,400,000 shares.

• PhaseBio Announces Pricing of Public Offering of Common Stock - Mar 18, 2021

  3/18/2021

  PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $3.50 per share.

• PhaseBio Announces Proposed Public Offering of Common Stock

  3/17/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PhaseBio expects to grant the underwriters a 30-day option to purchase additional shares of its common stock

• PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

  3/15/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and provided an update on clinical trial activities.

• PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

  3/11/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, and BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a commercial scale supply agreement for the production of bentracimab,

• PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences

  2/26/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the company will be participating in two upcoming virtual investor conferences.

•  PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021

  2/24/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it will host a virtual Investor and Analyst Day on March 15, 2021 from 12:00 p.m. to 2:00 p.m. ET.

• PhaseBio Announces Dosing of First Patient in European Union as Part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

  1/28/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that in conjunction with its financing and co-development partner for the European Union and China, SFJ Pharmaceuticals, PhaseBio has expanded its pivotal Phase 3 REVERSE-IT trial for its lead product candidate bentracimab into the European Union,

• PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil for the Treatment of Pulmonary Arterial Hypertension at 15th Pulmonary Vascular Research Institute Virtual World Congress

  1/27/2021

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of data from a Phase 1b/2a pilot study highlighting three patients who received pemziviptadil (PB1046)

• PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results

  11/12/2020

  Expanded pivotal Phase 3 REVERSE-IT trial of product candidate bentracimab (PB2452) for reversal of antiplatelet effects of ticagrelor into Canada and dosed first patients outside the United States Resuming enrollment in ongoing Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension

• PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

  11/11/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the Stifel

• PhaseBio Provides Pemziviptadil (PB1046) Program Update

  10/23/2020

  VANGARD trial discontinued due to evolving COVID-19 treatment landscape, recent feedback from FDA regarding regulatory and development path, and interim analysis of trial data Enrollment expected to resume for ongoing Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH)

• PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor

  10/6/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has expanded its pivotal Phase 3 REVERSE-IT trial for its lead product candidate bentracimab